Disease: Invasive fungal infections

Usefulness of Serum as a Non-Invasive Sample for the Detection of Histoplasma capsulatum Infections: Retrospective Comparative Analysis of Different Diagnostic Techniques and Quantification of Host Biomarkers

mycolabadmin

This study evaluated how well different blood tests can detect histoplasmosis, a serious fungal infection caused by Histoplasma capsulatum. Researchers compared three types of tests: those detecting fungal antigens, those detecting antibodies the body produces against the fungus, and DNA-based tests. They found that the best test depends on whether the patient’s immune system is functioning normally or is weakened by HIV, and using a combination of tests provides the most reliable diagnosis. The study also identified specific immune markers in the blood that are elevated in infected patients, which could help predict disease severity.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

mycolabadmin

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Read More »

In vitro activity of SF001: a next-generation polyene versus amphotericin B

mycolabadmin

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Read More »

Occurrence of Pathogenic and Allergenic Molds in the Outdoor and Indoor Environment of a Major Hospital and Molecular Epidemiology of Aspergillus fumigatus in Kuwait

mycolabadmin

Researchers in Kuwait found many types of mold in and around a hospital, with some being resistant to common antifungal medications. They discovered that the same mold species were found both outdoors and in the hospital environment, suggesting patients could catch infections from the surrounding air. The study identified molds that could cause serious infections in vulnerable patients and found that about 10% of environmental samples contained drug-resistant strains that were also found in sick patients.

Read More »
Scroll to Top